KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Debt (2017 - 2025)

Historic Total Debt for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $36.3 million.

  • Aquestive Therapeutics' Total Debt rose 1595.05% to $36.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.3 million, marking a year-over-year increase of 1595.05%. This contributed to the annual value of $32.5 million for FY2024, which is 1814.75% up from last year.
  • Aquestive Therapeutics' Total Debt amounted to $36.3 million in Q3 2025, which was up 1595.05% from $35.0 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Total Debt registered a high of $54.2 million during Q1 2022, and its lowest value of $27.5 million during Q4 2023.
  • Its 5-year average for Total Debt is $40.0 million, with a median of $39.2 million in 2023.
  • Its Total Debt has fluctuated over the past 5 years, first soared by 4517.67% in 2021, then plummeted by 4720.79% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' Total Debt (Quarter) stood at $53.6 million in 2021, then dropped by 2.67% to $52.1 million in 2022, then crashed by 47.21% to $27.5 million in 2023, then rose by 18.15% to $32.5 million in 2024, then increased by 11.5% to $36.3 million in 2025.
  • Its Total Debt was $36.3 million in Q3 2025, compared to $35.0 million in Q2 2025 and $33.8 million in Q1 2025.